Aprea Therapeutics (NASDAQ:APRE) Posts Earnings Results, Beats Expectations By $0.20 EPS

Aprea Therapeutics (NASDAQ:APRE) posted its quarterly earnings data on Tuesday. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.20, Zacks reports. The firm had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.15 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%.

Aprea Therapeutics Stock Down 3.1 %

Shares of NASDAQ:APRE opened at $2.19 on Wednesday. Aprea Therapeutics has a 12-month low of $2.15 and a 12-month high of $6.80. The firm has a market capitalization of $11.90 million, a P/E ratio of -0.78 and a beta of 0.82. The firm has a fifty day moving average of $3.12 and a two-hundred day moving average of $3.26.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on APRE shares. Wedbush reiterated an “outperform” rating and set a $11.00 price target on shares of Aprea Therapeutics in a report on Tuesday. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Aprea Therapeutics in a research report on Wednesday, January 15th.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.